Floatz logo

Moderna Covid-19 Vaccine Rna

Secondary Progressive Multiple Sclerosis

Novartis PharmaceuticalsvaccinePhase 4 / ApprovedDormant
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
47/ 100
Competitive Position
89/ 100

Competitive context

35 Active assets in the Secondary Progressive Multiple Sclerosis cohort.

Asset / SponsorPhaseRating
Siponimod
Novartis Pharmaceuticals
Phase 4BBB
Fampridine
University College Dublin
Phase 4BBB
Rituximab
Cairo University
Phase 3BB
bnt162
Novartis Pharmaceuticals
Phase 4BB
mis416
Innate Immunotherapeutics
Phase 2BB

View all 50 →

Same molecule, other indications

Moderna Covid-19 Vaccine Rna is also rated in:

neoplasmDormant
CCC
Indicative · Phase 2
55 / 100
View asset →
AL amyloidosisActive
CCC
Indicative · Phase 2
55 / 100
View asset →
multiple sclerosisActive
CCC
Indicative · Phase 2
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →